Supplemental material
Nephrology
Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review
, 
, , , , , , , , & show all
Roberto Pecoits-FilhoGeorge Institute for Global Health, Newtown, NSW, Australia; ;School of Medicine Pontificia Universidade Catolica do Parana, Curitiba, PR, Brazil; http://orcid.org/0000-0002-0255-6710
http://orcid.org/0000-0002-0255-6710, , , Samuel RochetteAnalysis Group, Inc, Montreal, QC, Canada; http://orcid.org/0000-0001-5412-2351
http://orcid.org/0000-0001-5412-2351, Philippe Thompson-LeducAnalysis Group, Inc, Montreal, QC, Canada; Correspondence[email protected]
http://orcid.org/0000-0001-9047-3941
http://orcid.org/0000-0001-9047-3941, , , Ana BozasAkebia Therapeutics, Cambridge, MA, USA; http://orcid.org/0000-0003-4231-1774
http://orcid.org/0000-0003-4231-1774, & show allRelated Research Data
Erythropoietin Therapy, Hemoglobin Targets, and Quality of Life in Healthy Hemodialysis Patients: A Randomized Trial
Source:
American Society of Nephrology (ASN)
Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review
Source:
Figshare
A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients
Source:
Oxford University Press (OUP)
Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients
Source:
American Society of Nephrology (ASN)
Systematic review of the impact of erythropoiesis-stimulating agents on fatigue in dialysis patients
Source:
Oxford University Press (OUP)
Spectrum and Burden of Erythropoiesis-Stimulating Agent Hyporesponsiveness Among Contemporary Hemodialysis Patients
Source:
Elsevier BV
Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis
Source:
Oxford University Press (OUP)
Health-related quality of life in CKD Patients: correlates and evolution over time.
Source:
American Society of Nephrology (ASN)
Erythropoietin resistance: the role of inflammation and pro‐inflammatory cytokines
Source:
Oxford University Press (OUP)
Red Blood Cell Transfusion Risks in Patients with End-Stage Renal Disease
Source:
Wiley-Blackwell
A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
Source:
Massachusetts Medical Society
Prevalence of Anemia in Chronic Kidney Disease in the United States
Source:
Public Library of Science (PLoS)
The Economic Burden of Chronic Kidney Disease and End-Stage Renal Disease
Source:
Elsevier BV
Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China
Source:
Oxford University Press (OUP)
Anemia Management Trends in Hospital-Based Dialysis Centers (HBDCs), 2010 to 2013
Source:
Elsevier BV
Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia
Source:
Springer Nature
Notice
Source:
Elsevier BV
Diminished Quality of Life and Physical Function in Community-Dwelling Elderly With Anemia
Source:
Ovid Technologies (Wolters Kluwer Health)
A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
Source:
Massachusetts Medical Society
An update on the impact of pre-transplant transfusions and allosensitization on time to renal transplant and on allograft survival
Source:
Springer Nature
International Comparisons to Assess Effects of Payment and Regulatory Changes in the United States on Anemia Practice in Patients on Hemodialysis: The Dialysis Outcomes and Practice Patterns Study
Source:
American Society of Nephrology (ASN)
The Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Who Are Receiving Hemodialysis and Epoetin
Source:
Massachusetts Medical Society
The minimal clinically important difference raised the significance of outcome effects above the statistical level, with methodological implications for future studies
Source:
Elsevier BV
The Effect of Erythropoietin-Stimulating Agents on Health-Related Quality of Life in Anemia of Chronic Kidney Disease
Source:
American College of Physicians
The Prevalence and Management of Anemia in Chronic Kidney Disease Patients: Result from the KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD)
Source:
Korean Academy of Medical Sciences (KAMJE)
Pharmacokinetics, pharmacodynamics and safety of single, oral doses of GSK1278863, a novel HIF-prolyl hydroxylase inhibitor, in healthy Japanese and Caucasian subjects
Source:
Elsevier BV
Intravenous iron and erythropoiesis-stimulating agents in haemodialysis: A systematic review and meta-analysis
Source:
Wiley-Blackwell
Balancing Innovation, Access, and Profits — Market Exclusivity for Biologics
Source:
New England Journal of Medicine (NEJM/MMS)
Safety of Intravenous Iron in Dialysis
Source:
American Society of Nephrology (ASN)
Comparison of methodologies to define hemodialysis patients hyporesponsive to epoetin and impact on counts and characteristics
Source:
Springer Nature
Dialysis patients treated with Epoetin α show improved exercise tolerance and physical function: A new analysis of the Canadian Erythropoietin Study Group trial
Source:
Wiley-Blackwell
Effects of Anemia and Left Ventricular Hypertrophy on Cardiovascular Disease in Patients with Chronic Kidney Disease
Source:
American Society of Nephrology (ASN)
An Economic Evaluation of Erythropoiesis-Stimulating Agents in CKD
Source:
Elsevier BV
Annual Iron Loss Associated with Hemodialysis
Source:
S. Karger AG
Burden of Illness Associated With Anaemia In Chronic Kidney Disease In Japan: A Literature Review
Source:
Elsevier BV
Iron Balance and the Role of Hepcidin in Chronic Kidney Disease
Source:
Elsevier BV
Notice
Source:
Elsevier BV
Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects
Source:
S. Karger AG
Association of Mild Anemia with Cognitive, Functional, Mood and Quality of Life Outcomes in the Elderly: The “Health and Anemia” Study
Source:
Public Library of Science (PLoS)
Dialysis patients treated with Epoetin alfa show improved anemia symptoms: A new analysis of the Canadian Erythropoietin Study Group trial
Source:
Wiley-Blackwell
Healthcare costs associated with nephrology care in pre-dialysis chronic kidney disease patients
Source:
Informa Healthcare
Diabetic Kidney Disease
Source:
American Society of Nephrology (ASN)
Health-related quality of life and estimates of utility in chronic kidney disease
Source:
Elsevier BV
Current and future chemical therapies for treating anaemia in chronic kidney disease
Source:
Informa UK Limited
The ascending rank of chronic kidney disease in the global burden of disease study
Source:
Oxford University Press (OUP)
Darbepoetin alfa (KRN321) is safe and effective when administered subcutaneously once every 2 or 4 weeks to patients on peritoneal dialysis in Japan
Source:
Springer Nature
Safety Issues in Iron Treatment in CKD
Source:
Elsevier BV
Four-Week Studies of Oral Hypoxia-Inducible Factor–Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia
Source:
American Society of Nephrology (ASN)
Association Between Changes in CMS Reimbursement Policy and Drug Labels for Erythrocyte-Stimulating Agents With Outcomes for Older Patients Undergoing Hemodialysis Covered by Fee-for-Service Medicare
Source:
American Medical Association (AMA)
Diabetic Kidney Disease
Source:
American Society of Nephrology (ASN)
Optimal anemia management reduces cardiovascular morbidity, mortality, and costs in chronic kidney disease
Source:
Elsevier BV
The Economic Impact of Pre-Dialysis Epoetin Alfa on Health Care and Work Loss Costs in Chronic Kidney Disease: An Employer's Perspective
Source:
Mary Ann Liebert Inc
Chapter 4: Red cell transfusion to treat anemia in CKD
Source:
Elsevier BV
The Impact of Lowering Haemoglobin Targets on Patterns of Erythropoiesis-Stimulating Agent Use in Patients on Haemodialysis
Source:
S. Karger AG
International trends in erythropoietin use and hemoglobin levels in hemodialysis patients
Source:
Elsevier BV
Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease
Source:
New England Journal of Medicine (NEJM/MMS)
Japanese haemodialysis anaemia management practices and outcomes (1999-2006): results from the DOPPS
Source:
Oxford University Press (OUP)
Diabetic Kidney Disease
Source:
American Society of Nephrology (ASN)
Health-Related Quality of Life and Hemoglobin Levels in Chronic Kidney Disease Patients
Source:
American Society of Nephrology (ASN)
Diabetic Kidney Disease
Source:
American Society of Nephrology (ASN)
Diabetic Kidney Disease
Source:
American Society of Nephrology (ASN)
Economic implications of non-adherence to treatment recommendations for hemodialysis patients with anemia
Source:
Wiley
Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia
Source:
Elsevier BV
Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review
Source:
Figshare
Intravenous Iron in Patients Undergoing Maintenance Hemodialysis
Source:
Massachusetts Medical Society
Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia
Source:
Massachusetts Medical Society
Linking provided by
